Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Breast Cancer

Clinical and regulatory intelligence for Breast Cancer with 59 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
59
Catalysts
0
Assets
31

Relevant assets

Alpelisib →
Bevacizumab →
BNT323 →
Boehringer →
Capecitabine →
Chimeric →
Datroway →
Digital →
Efficacy →
ERW316 →
Etcamah →
Fulvestrant →
Galectin-3 →
Giredestrant →
HER2 Positive →
Herceptin →
IBRANCE →
Integrating →
MRI →
Multicenter →
NCI →
Oncology →
palbociclib →
pembrolizumab →
PG2 →
Phase →
Pilot →
SRG-514 →
Talazoparib →
Targeting →
trastuzumab →

Relevant companies

AstraZeneca →
Beijing Biostar Pharmaceuticals Co., Ltd. →
Boehringer Ingelheim →
DB Pharma →
Eli Lilly →
Novartis →
oncology pharmaceutical companies →
PD-L1 →
Pfizer →
pharma companies in oncology →
Roche →
SURGE Therapeutics →

Recent signals(59)

ClinicalAugust 5, 2026

VR Program for Heart Health Education in Breast Cancer Survivors Undergoing Treatment

A study is underway to evaluate VR program aimed at improving heart health knowledge among breast cancer survivors receiving anthracyclines or trastuzumab.

ClinicalAugust 4, 2026

Study on Palbociclib Combinations in HR+HER2-MBC Initiated in Africa and Middle East

A non-interventional study is underway to gather data on treatment patterns and outcomes for palbociclib in HR+ HER2-positive metastatic breast cancer.

RegulatoryAugust 1, 2026

Datroway Approved in EU for Metastatic TNBC as First TROP2-Directed Therapy

Datroway has been approved in the EU as the only TROP2-directed therapy demonstrating overall survival benefit for first-line treatment in metastatic TNBC patients not eligible for immunotherapy.

ClinicalAugust 1, 2026

New Study Proposes Personalized Cardiac Surveillance for HER2 Positive Breast Cancer Patients

A new study will evaluate a personalized cardiac surveillance approach for HER2 positive breast cancer patients, potentially reducing unnecessary heart tests.

CompetitiveJuly 31, 2026

MammoVerse Study to Enhance Emotional Support for Breast Cancer Patients

A focus group study aims to identify gaps in emotional and mental health support for breast cancer patients.

ClinicalJuly 29, 2026

Study on Non-Contrast CT for Opportunistic Breast Cancer Screening Initiated

An observational study led by Fudan University is evaluating non-contrast chest CT for breast cancer screening.

ClinicalJuly 28, 2026

NCI Study on New Screening Methods for High-Risk Breast Cancer Women

The National Cancer Institute is conducting a study to explore new screening methods for early detection of breast and ovarian cancer in women with BRCA1 or BRCA2 mutations.

ClinicalJuly 27, 2026

Novartis initiates Phase I/II trial for ERW316 in HR+/HER2- breast cancer

Novartis is conducting Phase I/II trial to evaluate the safety and tolerability of ERW316 alone and in combination with endocrine therapies in HR+/HER2- breast cancer.

ClinicalJuly 25, 2026

Phase 3 Trial of SRG-514 in Triple Negative Breast Cancer Undergoing Surgery

A Phase 3 trial is underway to evaluate SRG-514, an intraoperative treatment for patients with triple negative breast cancer.

RegulatoryJuly 24, 2026

Etcamah Approved in EU for 1st-Line Advanced ER+ Breast Cancer

Etcamah (camizestrant) has been approved in the EU for use in combination with CDK4/6 inhibitors for 1st-line advanced ER-positive breast cancer, based on SERENA-6 trial results.

ClinicalJuly 22, 2026

Phase II Trial Optimizes Therapy for HER2+ Breast Cancer Patients Post-Surgery

A Phase II trial is testing reduced adjuvant therapy for HER2+ breast cancer patients who achieved a pathologic complete response after neoadjuvant treatment.

ClinicalJuly 19, 2026

Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC

The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.

ClinicalJuly 18, 2026

Phase II Study of L-Ornithine L-Aspartate and N-Acetylcysteine in HR+/HER2- Advanced Breast Cancer

A Phase II study is evaluating a combination treatment in HR+/HER2- advanced breast cancer patients who have progressed on standard therapies.

ClinicalJuly 17, 2026

Study on Sacituzumab Govitecan and Talazoparib in Metastatic Breast Cancer

A clinical trial is evaluating the combination of Sacituzumab Govitecan and Talazoparib in patients with metastatic triple-negative breast cancer.

RegulatoryJuly 15, 2026

FDA approves gedatolisib with fulvestrant for HR-positive, HER2-negative breast cancer

The FDA has approved gedatolisib in combination with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative breast cancer.

CompetitiveJuly 15, 2026

Boehringer Ingelheim Study on HER2-Altered Metastatic Breast Cancer Treatment Patterns

A new study by Boehringer Ingelheim aims to evaluate treatment patterns and outcomes in HER2-altered metastatic breast cancer patients in the U.S.

ClinicalJuly 15, 2026

Study on Pain Reporting in Women with Non-metastatic Breast Cancer During Chemotherapy

The study aims to assess pain levels reported by younger versus older women receiving pegfilgrastim during chemotherapy.

ClinicalJuly 13, 2026

Phase II Trial of DNA-guided Therapy for High Residual Risk ER+ HER-2 Negative Breast Cancer

A Phase II trial is underway evaluating DNA-guided second line adjuvant therapy for patients with high residual risk ER+ HER-2 negative breast cancer.

ClinicalJuly 13, 2026

MRI and Multiomics Integration for Precision Treatment in Luminal Breast Cancer

A study is underway to integrate MRI and multiomics data for non-invasive molecular typing in luminal breast cancer.

ClinicalJuly 12, 2026

LncRNA AC008406.3 Enhances Docetaxel Sensitivity in Breast Cancer via Cuproptosis

The study identifies LncRNA AC008406.3 as a regulator of docetaxel sensitivity in breast cancer through cuproptosis.

ClinicalJuly 11, 2026

Phase II/III Trial Evaluates Surgery vs. High-Dose Radiation for Limited Metastatic Breast Cancer

A randomized phase II/III trial is assessing the efficacy of adding stereotactic radiosurgery or surgery to standard care in limited metastatic breast cancer.

ClinicalJuly 11, 2026

Digital Tomosynthesis Mammography Shows Promise in Breast Cancer Screening

A randomized phase III trial suggests that digital tomosynthesis mammography may be superior to digital mammography for breast cancer screening.

ClinicalJuly 11, 2026

Study on Plasma Tumor DNA as Predictor in Early-Stage Breast Cancer Treatment

A study is investigating the use of plasma tumor DNA to predict treatment response in early-stage breast cancer patients undergoing neoadjuvant therapy.

ClinicalJuly 10, 2026

Novartis initiates study on Alpelisib and Fulvestrant for advanced HR+ breast cancer

Novartis is conducting a study to evaluate the efficacy and safety of alpelisib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer patients who have progressed after prior treatments.

ClinicalJuly 9, 2026

Pilot Study Combining Immunotherapy and Thermal Therapy in HER2-Negative Breast Cancer

A pilot study is underway to evaluate the combination of neoadjuvant chemotherapy, immunotherapy, and multimodal thermal therapy in HER2-negative breast cancer patients.

ClinicalJuly 9, 2026

Study on Diabetes Care Improvement for Breast Cancer Patients

A clinical trial is investigating the impact of trained diabetes care nurses on breast cancer patients with diabetes.

ClinicalJuly 8, 2026

Multicenter Trial Comparing Surgery and Systemic Therapy in Stage IV Breast Cancer

A national multicenter trial is underway to compare 5-year overall survival between surgery followed by systemic therapy and systemic therapy alone in Stage IV breast cancer patients with solitary bone metastases.

ClinicalJuly 8, 2026

PG2 Study to Evaluate Survival Benefits in Early Breast Cancer Patients Undergoing Adjuvant Therapy

The PG2 study aims to assess the survival benefits of adding APS to adjuvant chemotherapy in breast cancer patients.

ClinicalJuly 7, 2026

Study on Utidelone's Efficacy in HER-2 Negative Advanced Breast Cancer

A randomized controlled study is evaluating the efficacy of Utidelone Capsule versus Utidelone Injection in combination with Capecitabine for HER-2 negative advanced breast cancer.

ClinicalJuly 5, 2026

Study on Respiratory Muscle Strength Training in Breast Cancer Surgery Patients

A clinical trial is investigating the efficacy of respiratory muscle strength training to prevent muscle weakness in adults newly diagnosed with breast cancer undergoing surgery.

ClinicalJuly 5, 2026

Nursing-led Mobile Health Study Aims to Improve Outcomes in Breast Cancer Chemotherapy

A study is underway to evaluate the impact of mobile health information combined with nursing support on breast cancer patients undergoing chemotherapy.

ClinicalJuly 4, 2026

Integrating Immune Landscape Insights to Enhance Breast Cancer Management

The study highlights the heterogeneity of breast cancer and the potential of integrating immune parameters into treatment decision-making.

ClinicalJuly 4, 2026

Chimeric CCL2 and CCL8 Peptides Show Antitumor Activity in Breast Cancer

Chimeric peptides combining CCL2 and CCL8 with diphtheria toxin demonstrate effective antitumor activity against human breast tumors.

ClinicalJuly 3, 2026

Phase II Study of HER2 Imaging as Biomarker for T-DM1 in Advanced Breast Cancer

The ZEPHIR-02 trial will evaluate 89Zr-trastuzumab PET/CT as a predictive biomarker for T-DM1 treatment in HER2-positive mBC patients post T-DXd progression.

ClinicalJuly 1, 2026

Phase II Trial of Multi-epitope Vaccine in Triple Negative Breast Cancer Shows Promise

A randomized phase II trial is investigating the efficacy of a multi-epitope folate receptor alpha peptide vaccine combined with GM-CSF and cyclophosphamide in preventing recurrence of triple negative breast cancer.

ClinicalJuly 1, 2026

Study identifies SALL2 as a potential therapeutic target in breast cancer progression

The study explores the role of SALL2 in breast cancer progression, highlighting its potential as a therapeutic target.

ClinicalJuly 1, 2026

Study on Animated Video and Booklet to Enhance Breast Cancer Awareness in Palestinian Women

A randomized controlled trial will evaluate the effectiveness of an animated video versus an educational booklet in increasing breast cancer knowledge among Palestinian women aged 40-69.

ClinicalJune 27, 2026

Phase II Trial of Paclitaxel & Cyclophosphamide With/Without Trastuzumab in Breast Cancer

This phase II trial evaluates the efficacy and side effects of paclitaxel and cyclophosphamide with or without trastuzumab in previously untreated breast cancer patients.

ClinicalJune 25, 2026

Study on HER2 Expression in Breast Cancer Using [99mTc]Tc-ZHER2:4107 Initiated

[99mTc]Tc-ZHER2:4107 will be evaluated for its accumulation in breast cancer tumors with varying HER2 expression.

RegulatoryJune 25, 2026

FDA Approves Palbociclib with Trastuzumab for HR-positive, HER2-positive Breast Cancer

The FDA has approved palbociclib in combination with trastuzumab, with or without pertuzumab, for maintenance treatment in HR-positive, HER2-positive metastatic breast cancer.

ClinicalJune 25, 2026

Efficacy and safety of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer across altitudes

The study evaluates the efficacy and safety of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer across different altitudes.

RegulatoryJune 25, 2026

FDA Approves Pfizer’s IBRANCE for HR+, HER2+ Metastatic Breast Cancer Maintenance

The FDA has approved IBRANCE in combination with trastuzumab and endocrine therapy for HR+, HER2+ metastatic breast cancer maintenance treatment, based on the Phase 3 PATINA trial results.

ClinicalJune 24, 2026

Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer

Merck is conducting a clinical trial to evaluate sacituzumab tirumotecan in combination with pembrolizumab and chemotherapy for high-risk early-stage breast cancer.

ClinicalJune 24, 2026

Phase III Trial Evaluates Bevacizumab with Chemotherapy in HER-2 Positive Metastatic Breast Cancer

A phase III trial is investigating the efficacy of adding bevacizumab to first-line chemotherapy and trastuzumab in HER-2 positive metastatic breast cancer.

ClinicalJune 21, 2026

Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care

A study is evaluating the association between cancer cachexia and gut microbiota in breast cancer patients receiving home care, including the impact of a probiotic mixture.

ClinicalJune 21, 2026

Targeting Macrophage Cytokine Circuit Offers New Strategy Against TNBC Metastasis

Tumor-educated macrophages promote TNBC metastasis through a cytokine circuit, which can be disrupted pharmacologically.

ClinicalJune 20, 2026

Trial on Mobile Health Platform to Improve Adherence in Metastatic Breast Cancer Patients

A clinical trial is assessing the effectiveness of the CONCURxP platform in improving medication adherence among metastatic breast cancer patients on CDK4/6 inhibitors.

ClinicalJune 18, 2026

Study on De-escalation of Radiation Therapy in Node Negative Breast Cancer

A clinical trial is investigating the de-escalation of radiation therapy in women with clinically node negative breast cancer undergoing lumpectomy.

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated

A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.

ClinicalJune 17, 2026

Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer

A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Breast Cancer →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.